PPT-Flt3 Agonist Enhances Immunogenicity of Arenavirus-Based Vaccine Vector in Macaques

Archana Vidya Boopathy 1 Anurag Nekkalapudi 1 Bhawna Sharma 1 Sophie Schulha 2 Raphaela Wimmer 2 Debi Jin 1 Janette Sung 1 Jeffrey Murry 1 Mark Nagel 1 Brian Carr. Xiaoying Chen, . Timothy Hickling. , Paolo Vicini. PDM-NBE, Pfizer, USA. New technologies for immunogenicity assays/prediction. European Immunogenicity Platform February 23-25, 2015 . Complexity of Immunogenicity. . Nogal. , Gabriel Pineda,. Keith Neeves, Judy . Schoonmaker. ,. Delphi . Chatterjee. , Diane Ordway, . Erika . Tinoco. Goals and Outcomes. Unit. : Engineering recombinant DNA vaccines. Goal: To understand the molecular biology sequence of antigen . behavior. Peter . Smittenaar. *. , Klaus . Wunderlich. *. , Ray Dolan. Model-based and model-free systems. model-free . (habitual). Cached values: single stored value. Learned over many repetitions. TD prediction error. Intrarectal. Challenge with SHIV109CP3. Martin Markowitz MD. Aaron Diamond AIDS Research Center. An affiliate of the Rockefeller University. New York, New York. USA. Conflict of Interest. Research grants. Program Introduction . Technologies Used to Produce Therapeutic mAbs. Molecular Structures of Biologic Drugs Used to Treat Psoriasis. Biologics: Consequences of ADAs. Consequences of . ADAs. Biologics: Types of ADAs. proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Module 10: . Acute Myeloid Leukemia . Drs Stone and . Pollyea. . Do you have any patients in your practice with.... phase . 1 clinical trial in HIV-1 infected . patients. Escaich Sonia, . COO . BIOSANTECH . SA.. Tat is a virulence factor of HIV. Transactivator. of transcription (Tat) of HIV-1 is essential for the viral . REFERENCE T - : Preclinical Assessment and Mitigation L.P. Cousens 1 , V. Jawa 2 , M. Awwad 3 , E. Wakshull 4 , H. Kropshofer 5 , W. Martin 1 , A.S. De Groot 1,6 1 EpiVax, Inc . USA , 2 Amgen Inc . R4P 2021. Eric Arts on behalf of the VSV-HIV vaccine team. To work with Dr. Chris Parks and IAVI to develop new VSV-based HIV vaccines that would propagate independent of VSV G and/or HIV-1 Env . To design new HIV-1 gp140 chimeras containing transmembrane and cytoplasmic tails from different viruses for optimal expression and antigen presentation on VSV particles. Biotherapeutics. Biowaivers. and . Biosimilars. – 2014. October 27-29, 2014 . Hyderabad, India. Surendra J. Chavan, Ph.D.. CTO & Founder. Quantimmune. Solutions PVT. Subsidiary of . Accutest. 1 of 2 Arenaviridae The Arenaviridae are a family of viruses whose members are generally associated with rodent - transmitted diseases in humans. Each virus usually is associated with a particular r Antigens . Adjuvants . Keep vaccines safe and long lasting. Preservatives . Stabilizers. Used during the production of vaccines. Cell culture materials. Inactivating ingredients. Antibiotics. VACCINE COMPONENTS. Prof. Ibrahim A. . Alsarra. Professor . of . Pharmaceutics . and Pharmaceutical . Biotechnology.                                  .  . Immunogenicity. : the capability of a specific substance to induce an unwanted immune response that is triggered by more than one single factor.. 03 February 2021. Dr B Semete. Contents. COVID-19 vaccines. Ivermectin. access program. Summary of the most advanced vaccines in development. Vaccine applications submitted to SAHPRA. Vaccine developer.